We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New Ablation Technique Shows Promise for Hard-to-Treat Ventricular Tachycardia Heart Rhythms

By HospiMedica International staff writers
Posted on 18 Aug 2022
Print article
Image: First-in-human trial has shown promise for hard-to-treat ventricular tachycardia heart rhythms (Photo courtesy of Pexels)
Image: First-in-human trial has shown promise for hard-to-treat ventricular tachycardia heart rhythms (Photo courtesy of Pexels)

Therapies of medication and traditional ablation, which uses heat or cold to scar small areas of heart tissue, may not be enough to prevent ventricular tachycardia, an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide. People with ventricular tachycardia live with the potential of sudden cardiac death from irregular electrical signals in the heart. Therefore, many patients also have an implantable cardioverter-defibrillator (ICD) to address dangerous arrhythmias. While an ICD shock corrects the heart's rhythm, it does not prevent arrhythmia. Corrective shocks are also stressful for patients and can reduce quality of life, especially if needed frequently. Now, a new ablation technique for patients with ventricular tachycardia has been used in a first-in-human multicenter trial that involved several methods to directly eliminate abnormal heart tissue which causes life-threatening rhythm.

The trial conducted by researchers at Mayo Clinic (Rochester, MN, USA) tested needle ablation using in-catheter, heated, saline-enhanced, radio frequency energy, also known as SERF, to substantially increase heat transfer, compared to conventional ablation methods. The new process produces deeper, controllable lesion scars at sites inside the heart muscle. The catheter can accurately control the ablation size and treat tissue that is deeper in the heart wall, which is where life-threatening arrhythmias that cause ventricular tachycardia are often found.

In the trial, 32 participants from six centers underwent needle electrode ablation. Each had experienced multiple episodes of ventricular tachycardia that did not respond to drug therapy after an ICD was implanted and standard ablation was done. These patients had about 45 shocks from their defibrillator in the six months before their procedure. For 31 of these 32 patients, their clinical ventricular tachycardia was eliminated immediately at the end of the procedure. Device therapies, such as shock or pace regulation, were reduced by 89% during the five-month follow-up period. Five patients in this high-risk group had complications, primarily in the earlier procedures. The next step in this research is a larger clinical trial with approximately 150 patients to prove the findings and demonstrate the safety of the new SERF technology.

"This preliminary trial is important because it suggests that there is a new way to treat problematic ventricular tachycardia by reducing or eliminating the shocks that ICDs deliver. It appears to be effective in achieving this goal," said Douglas Packer, M.D., a cardiac electrophysiologist at Mayo Clinic, first author and principal investigator of the study. "For clinicians, it provides hope that treatment in the electrophysiology lab may be effective, even if other treatments failed. For patients, it provides hope that their quality of life can be improved."

Related Links:
Mayo Clinic


Print article
IIR Middle East

Channels

Surgical Techniques

view channel
Image: The EASEE minimally invasive brain pacemaker has received CE certification (Photo courtesy of Precisis GmbH)

World's First Minimally Invasive Brain Pacemaker Treats Epilepsy

The treatment of patients with epilepsy always begins with medication. However, for decades there has unfortunately been a consistently large group of around 30% of all patients for whom pharmacological... Read more

Patient Care

view channel
Image: The biomolecular film can be picked up with tweezers and placed onto a wound (Photo courtesy of TUM)

Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients

Conventional bandages may be very effective for treating smaller skin abrasions, but things get more difficult when it comes to soft-tissue injuries such as on the tongue or on sensitive surfaces like... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.